Načítá se...
A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
WHAT IS KNOWN AND OBJECTIVE: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are one of the preferred approved treatment options for people with type 2 diabetes (T2D) and inadequate glycaemic control. The objective of this review is to provide a general clinical overview of the similarities an...
Uloženo v:
| Vydáno v: | J Clin Pharm Ther |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7540167/ https://ncbi.nlm.nih.gov/pubmed/32910490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcpt.13230 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|